Innovent Biologics, Inc.
↗Suzhou, China
Innovent Biologics is a leading Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of high-quality innovative medicines. The company operates a fully integrated platform covering the entire drug development lifecycle, from discovery and preclinical research to clinical development and commercial-scale manufacturing.
Innovent has a diversified pipeline of over 30 assets targeting major therapeutic areas including oncology, metabolic diseases, autoimmune diseases, and cardiovascular diseases. The company is known for its strong commercial portfolio, including the PD-1 inhibitor Tyvyt (sintilimab), and its strategic focus on advanced modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and cell therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1B-$2B
Founded:2011
Ownership:public
Status:operating
FUNDING
Total Raised:$1.3B
Investors:Eli Lilly and Company, Fidelity Investments, China Life, Hillhouse Capital, Temasek
STOCK
Exchange:HKG
Ticker:1801
Market Cap:$20.1B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Monoclonal antibody, Bispecific antibody, Antibody-drug conjugate (ADC), Small molecule, Cell therapy
Active Trials:341
Trial Phases:Phase 3: 4
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:InnoPinnacle
Key Partnerships:Eli Lilly (Oncology), Sanofi (Oncology), Roche (ADC), Takeda (Oncology), Incyte, Adimab
COMPETITION
Position:Leader
Competitors:BeiGene, Sino Biological, Mabworks
LEADERSHIP
Key Executives:
Yu Dechao - Founder, Chairman & CEO
Liu Yongjun - President
Scientific Founders:Yu Dechao
Board Members:Charles Leland Cooney, Hsu I Yin Joyce, Gary Zieziula, Lu Shun, Chen Shuyun
LINKS
Website:innoventbio.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Innovent Biologics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Innovent Biologics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.